Drug Trial Radar · NCT05646563
Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Jul 2029
Study completion Aug 2030
Sponsor
- Lead sponsor
- NovelMed TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 in PNH patients undergoing complement-inhibitor therapy with Soliris.
Conditions
- Paroxysmal Nocturnal Hemoglobinuria
Interventions
NM8074Drug
NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
SolirisDrug
Complement C5 blocker administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Study Day 105
- Number of Participants with Antidrug Antibodies (ADAs) to NM8074Time frame: Up to Study Day 105
- Change from Baseline or Percent Change from Baseline in Hemoglobin (Hgb) LevelsTime frame: Up to Study Day 105
- Change from Baseline or Percent Change from Baseline in Lactate Dehydrogenase (LDH) LevelsTime frame: Up to Study Day 105
- Change from Baseline or Percent Change from Baseline in Number of Packed Red Blood Cell (pRBC) TransfusionsTime frame: Up to Study Day 105
- Percent Change from Baseline in Levels of Membrane Attack Complex (MAC) via Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Levels of MAC via Classical Pathway (CP) of Complement ActivityTime frame: Up to Study Day 105
- Percent Change from Baseline in Levels of Complement Component C3b via Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Levels of C3b via Classical Pathway (CP) of Complement ActivityTime frame: Up to Study Day 105
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.